Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending January 26, 2018. The report details a regulatory milestone for GSK's respiratory franchise in partnership with Innoviva, Inc., specifically regarding the product Relvar Ellipta (fluticasone furoate/vilanterol).
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity figures. This document is a regulatory announcement rather than a financial results report.
Material Changes and Regulatory Developments
- CHMP Positive Opinion: The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending a label update for Relvar Ellipta.
- Indication Expansion: The update allows for the use of once-daily Relvar Ellipta in patients whose asthma is already adequately controlled on both an inhaled corticosteroid (ICS) and a long-acting beta-2-agonist (LABA).
- Clinical Evidence: The submission was supported by a non-inferiority lung function study showing patients could switch from twice-daily Seretide Accuhaler to once-daily Relvar Ellipta without compromising lung function.
- Safety Profile: No new safety signals were identified; adverse event data remained consistent with the known safety profile for the drug.
Outlook, Management Commentary, and Risks
Management Commentary: GSK executives highlighted that many asthma patients in Europe experience symptoms despite being on twice-daily therapy. The new option provides physicians with a once-daily alternative for patients with adequately controlled asthma. Innoviva's CEO noted that the opinion supports individualized treatment management.
Outlook: A final decision on the marketing authorization update by the European Commission is anticipated towards the end of the first quarter of 2018.
Risks and Contingencies:
- Regulatory Risk: The CHMP opinion is a recommendation; final approval by the European Commission is required.
- Safety Warnings: The filing reiterates contraindications and risks associated with Relvar Ellipta, including pneumonia (particularly in COPD patients), cardiovascular effects, and systemic corticosteroid effects (e.g., adrenal suppression, bone density loss).
- Forward-Looking Statements: Both GSK and Innoviva caution that actual results may differ materially from projections due to risks described in their respective annual reports.
Investor Verification Checklist
- Confirm the final marketing authorization decision by the European Commission in Q1 2018.
- Review the commercial impact of the label expansion on Relvar Ellipta sales in the European market.
- Monitor safety data post-approval, specifically regarding pneumonia incidence in the expanded patient population.
- Verify the royalty revenue implications for partner Innoviva, Inc. based on the expanded indication.